Gritstone Oncology racks up $102 mln Series A

By Iris Dorbian — 1 month ago

San Francisco Bay area-based Gritstone Oncology, a cancer immunotherapy company, has raised $102 million in Series A financing. The investors included Versant Ventures, The Column Group, Clarus Ventures, Frazier Healthcare Partners, Redmile Group, Casdin Capital and Transformational Healthcare Opportunity.


Flexus Biosciences rakes in $38 mln Series B

By Iris Dorbian — 12 months ago

Flexus Biosciences has raised $38 million in Series B funding. The investors were Kleiner Perkins Caufield & Byers, The Column Group and Celgene. Also, the firm has named Dr. David Goeddel, a managing partner at TCG, to its board of directors and Dr. Alexander Rudensky as chairman of its clinical and scientific advisory board. Based in San Carlos, Calif., Flexus is a cancer immunotherapy firm.


Nurix launches with Series B

By Angela Sormani — 2 years ago

Third Rock Ventures and The Column Group have backed the launch of Nurix with a $25.1 million Series B financing. Nurix develops therapies that modulate the ubiquitin proteasome system.


Igenica Closes $33 Million in Series C Funding

By Jonathan Marino — 3 years ago

California-based antibody biopharma company Igenica has raised $33 million in a Series C round led by new investor Third Rock Ventures. Existing backers The Column Group, Orbimed Advisors and 5AM Ventures participated in the round; Igenica has raised about $55 million to date. PRESS RELEASE: BURLINGAME, Calif., June 12, 2012 /PRNewswire/ — Igenica, Inc., a […]


Cyterix Nabs $9.2M Round

By Jonathan Marino — 4 years ago

Cyterix Pharmaceutics has landed $9.2 million from The Column Group and SV Life Sciences for its Series A Round. As part of the transaction, Tim Kutzkey, Ph.D., Partner at The Column Group, and Lutz Giebel, Ph.D., Managing Partner at SV Life Sciences, have joined the Cyterix Board of Directors. The company was founded in 2010.


Constellation Pharmaceuticals Closes on $15M

4 years ago

Constellation Pharmaceuticals has raised $15 million in an extension to its Series B round, the company announced Monday. Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures – all existing shareholders – participated in the round. The latest infusion will help Constellation move its products toward clinical development. The company develops small molecule therapeutics for the treatment of cancer, inflammatory and immunologic disorders and other diseases.


Aragon Pharmaceuticals Announces $8 Million Series A Financing

By PEHub Administrator — 7 years ago

Aragon Pharmaceuticals raised $8 million in Series A financing led by The Column Group and OrbiMed Advisors. Press release: Aragon Pharmaceuticals today announced it has raised $8 million in Series A financing led by The Column Group and OrbiMed Advisors. Funds from the Series A financing will be used to discover and develop new small […]